Medicines Patent Pool Centers On Consolidation In Its New Three-Year Strategy

Organization Aims To Conclude 10 Licenses, Develop Five Products And Transfer mRNA Tech To 10 Manufacturers

The Medicines Patent Pool’s new strategy could open the door to significant new opportunities for generic drug suppliers across low- and middle-income countries, as it explores its remit in new fields such as biologics, early-stage drug development and even – possibly – antimicrobial resistance.

2023, 2024 and 2025 sprayed onto a road
MPP has opted for a consolidated, three-year strategy • Source: Shutterstock

“This is my last job,” said Medicines Patent Pool executive director Charles Gore. “I’ve worked in global public health for the last 20 plus years and I am only interested in what difference we can make as an organization. I’m not interested in empire building or the whole kind of ego trip that there’s unfortunately a bit too much of in public health. It’s about just seeing where we can make a difference.”

The MPP has recently announced its new strategy, which will span from this year through to 2025, opting for a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Bakers And Fishermen: How Biosimilars Manufacturers Are Bridging The Skills Gap

 
• By 

At Medicines for Europe’s annual conference in Brussels, executives from Polpharma Biologics and Gedeon Richter spoke about the challenges in finding biosimilars manufacturing staff with the right backgrounds – and how they are looking to other industries to bridge the skills gap.

Lupin And Zentiva Throw Hat Into The Ring On Biosimilar Cimzia

 
• By 

The announcement by Lupin and Zentiva of a development and commercialization deal on a certolizumab pegol biosimilar candidate has revealed a new potential challenger to Alvotech’s AVT10, previously thought to be the only Cimzia rival in development.

China’s Qilu Looks To US Hospitals Market With Sagent Injectables Collaboration

 
• By 

Sagent and Qilu will look to enhance access, reduce treatment costs, and strengthen supply chains after striking an alliance for a portfolio of the Chinese firm’s complex injectables.